were used in this study. Spontaneous ciprofloxacin-resistant mutants of FDA 209-P were isolated by the direct plating technique described below. Heart infusion broth (Nissui Seiyaku Co., Ltd.) was used to preculture the strains and to collect the cells.
The new quinolones have potent antibacterial activities against gram-positive and gram-negative bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa (2, 5, 6, 8, 15, 19) . However, resistance in S. aureus, especially in methicillin-resistant S. aureus (MRSA) isolates, and P. aeruginosa has increased, possibly owing to excessive or inappropriate use of new quinolones (12) . It has been reported previously (1, 3, 10) that the mechanism of new quinolone resistance in clinical isolates of P. aeruginosa is a mutation in the A subunit of DNA gyrase and alteration in outer membrane permeability. Although the presence of an efflux mechanism in S. aureus has not yet been proved, it was recently inferred on the basis of increased quinolone accumulation by intact cells following treatment with energy inhibitors (21, 22) . The inhibitory effects of quinolones on the DNA gyrase from fluoroquinolone-resistant S. aureus isolates were not examined, however, because of the difficulty encountered in the purification of DNA gyrase from these organisms. To this point, there have been no reports on the purification and the inhibitory properties of DNA gyrase from fluoroquinolone-resistant S. aureus.
In this report, we describe the purification and properties of subunit A and B proteins of DNA gyrase from a clinically isolated fluoroquinolone-resistant MRSA, S. aureus 6171.
MATERIALS AND METHODS
Bacterial strains and culture media. Fluoroquinolone-resistant S. aureus 6171 and quinolone-susceptible S. aureus FDA 209-P (20) were used in this study. Spontaneous ciprofloxacin-resistant mutants of FDA 209-P were isolated by the direct plating technique described below. Heart infusion broth (Nissui Seiyaku Co., Ltd.) was used to preculture the strains and to collect the cells.
Isolation of ciprofloxacin-resistant mutants of FDA 209-P. A single colony of strain FDA 209-P was inoculated into 10 ml of heart infusion broth, and aliquots of 0.1 ml of the overnight culture were plated (109 CFU) onto the surface of * Corresponding author.
heart infusion agar (Nissui Seiyaku Co., Ltd.) plates containing 0.39 ,ug of ciprofloxacin per ml. Resistant colonies (single-step mutants) were counted after 48 h of incubation. The double-step (selective concentration of ciprofloxacin, 1 .56 ,ug/ml) and triple-step (selective concentration of ciprofloxacin, 12.5 ,ug/ml) mutants were obtained in the same manner from among the single-and double-step mutants, respectively. Six representative colonies were selected from among the triple-step mutants, and the drug susceptibilities of these strains were tested with ofloxacin, ciprofloxacin, enoxacin, and sparfloxacin. From the MICs, one triple-step mutant (mutant 19) that was moderately resistant to both ciprofloxacin and sparfloxacin was chosen for further study.
Antibacterial agents and susceptibility. Ciprofloxacin (Bayer AG), sparfloxacin and enoxacin (Dainippon Seiyaku Co. Ltd.), ofloxacin (Daiichi Seiyaku Co., Ltd.), and novobiocin (Sigma Chemical Co.) were used. The MICs were determined by a twofold agar dilution method recommended by the Japan Society of Chemotherapy. One loopful (ca. 106 CFU) of a diluted culture broth was inoculated onto heart infusion agar plates. MICs were determined after incubation at 37°C for 18 h.
Isolation of DNA gyrase. S. aureus cells grown in heart infusion broth were collected by centrifugation at 10,000 x g, washed with TGED buffer (50 mM Tris hydrochloride [pH 7.5], 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol), and suspended in 100 ml of the same buffer; and 100 ml of glycerol (Wako) was added. Diisopropylfluorophosphate (final concentration, 1 mM; Sigma) was then added to the cell suspension. The cell suspension (ca. 20g) was frozen at -80°C for 2 h and was then thawed at 4°C; this process was repeated 10 times. All subsequent steps were performed at 0 to 4°C. After the cell suspension was sonicated 40 times for 15 s each time at output control 7 (model W-225R; Heat Systems-Ultrasonics, Inc.) in ice, 25 ml of 1 M KCl, 10 ml of 0.5 M EDTA, 0. DNA supercoiling assay and ID50 determinations. The supercoiling activity of DNA gyrase and 50% inhibitory doses (ID50s) of quinolones were examined by using modifications of methods described in previous reports (18) . One unit of gyrase, as defined by Gellert et al. (7) , is that amount of enzyme which catalyzes the conversion of one-half of the relaxed closed-circular DNA to the supercoiled form in 2 h at 370C in an agarose reaction mixture containing 0.15 ,ug of DNA. Gyrase subunit A activity was determined in the presence of excess gyrase subunit B. Gyrase subunit B activity was determined in the presence of excess gyrase subunit A. Plasmid pBR322 DNA, which was used as the substrate in the supercoiling assay of DNA gyrase, was relaxed by use of topoisomerase I (Bethesda Research Laboratories, Inc., Gaithersburg, Md.) in a manner similar to that described previously (18) . The reaction mixture (20 with a laser densitometer (LKB). The ID50 was calculated from the density of the band of supercoiled DNA.
Accumulation of sparfioxacin and ciprofloxacin by S. aureus. The accumulation of sparfloxacin and ciprofloxacin by intact cells was measured by the method of Hirai et al. (9), with slight modification. The bacteria were grown to the late logarithmic phase (A550 = 1.0) in antibiotic medium 3 (Difco), and sparfloxacin and ciprofloxacin were added to the bacterial culture at final concentrations of 10 pug/ml. The culture was incubated at 37°C with shaking. When needed, an energy inhibitor, carbonyl cyanide m-chlorophenylhydrazone (CCCP; Sigma), was added to the culture to a final concentration of 100 ,uM 10 min after the addition of the quinolone. At various time intervals, 10 ml of the culture was rapidly chilled. The cells were collected by centrifugation, washed twice with 5 ml of 0.1 M phosphate buffer (pH 7.2), and resuspended in 1 ml of the same buffer. Lysostaphin (Sigma) was added to the suspension at a final concentration of 60 ,ug/ml. Each sample was allowed to stand at 37°C for 30 min and was then immersed in boiling water for 10 mim; this was followed by centrifugation. The concentration of the quinolone in the supernatant was measured by bioassay by using E. coli NIH JC-2 (9).
RESULTS
Selection of ciprofloxacin-resistant mutants. Single-step mutants of S. aureus FDA 209-P arose at a frequency of 7.2 x 10-6 when the isolate was plated on selective medium containing 0.39 ,ug of ciprofloxacin per ml. However, singlestep mutants could not be isolated at concentrations above 0.78 ,ug of ciprofloxacin per ml. Double-step mutants arose at frequencies of 6.4 x 10-' and 7.7 x 10' when single-step mutants selected with 0.39 ,ug of ciprofloxacin per tml were plated onto selective media containing 1 isolates to sparfloxacin and ciprofloxacin are given in Table  2 . The susceptibilities of 139 strains of MRSA to sparfloxacin and ciprofloxacin were similar to those reported previously (11) and were divided into two groups on the basis of their susceptibilities to sparfloxacin (Tables 1 and 2 ). Group 1 strains were moderately or highly resistant to hydrophilic quinolones but were susceptible to the hydrophobic quinolone (sparfloxacin), and group 2 strains were resistant to all of the fluoroquinolones, including the hydrophobic quinolone (sparfloxacin). From among the group 2 strains, we chose S. aureus 6171, which was highly resistant to both ciprofloxacin and sparfloxacin, for purification of its DNA gyrase.
The susceptibilities of S. aureus FDA 209-P, mutant 19, and 6171 to quinolones are given in Table 3 . S. aureus FDA 209-P was susceptible, S. aureus mutant 19 was moderately resistant, and S. aureus 6171 was highly resistant to the quinolones.
Isolation of DNA gyrase. The elution patterns on the novobiocin-Sepharose CL-6B affinity column obtained with 0.2 M NaCl-, 2 M NaCl-, and 2 M NaCl-5 M urea-containing TGED buffers of S. aureus 6171 are given in Fig. 1 . Similar elution patterns were also obtained with S. aureus FDA 209-P and mutant 19 (data not shown). The highest enzymatic activity of the subunit A protein was near the 0.2 M NaCl peak of A280. Neither exonuclease nor restriction enzyme was found in these fractions. On the other hand, 2 M NaCl fractions had no enzymatic activity of subunit A protein, and we could remove many impurities such as exonuclease with TGED buffer containing 2 M NaCl. The highest enzymatic activity of the subunit B protein was also near the 2 M NaCl-5 M tirea peak of A280.
Total protein concentrations and unit activity determinations are presented in Table 4 . The A-and B-subunit preparations did not possess supercoiling activity when they were present alone in a gyrase reaction, but they did exhibit supercoiling activity when they were combined. The major protein bands in the A-and B-subunit preparations from FDA 209-P, mutant 19, and 6171 were approximately 85,000 and 80,000 Da, respectively (gel not shown). Scanning of the subunit lanes indicated that each subunit was at least 90% pure.
When the addition of ATP to the reaction mixture was omitted, there was no supercoiling activity for any of the three enzymes purified from FDA 209-P, mutant 19, and 6171. This result was similar to results of a recent study (20) .
ID50 determinations. The supercoiling activities of reconstituted As Bs (s, susceptible) and Ar 13s (r, resistant) gyrases are shown in Fig. 2 . Sparfloxacin inhibited the activity of As BS gyrase (Fig. 2B) , and complete inhibition occurred at 50 ,ug/ml (Fig. 2B, lane c) . In contrast, lanes b to d in Fig. 2A were the same as lane a in Fig. 2A , which contained sparfloxacin at high concentrations. The Ar Bs gyrase was resistant to 800 ,ug of sparfloxacin per ml. The ID50s of ciprofloxacin, sparfloxacin, and novobiocin against the supercoiling activities of reconstituted Ar Br, A' Bs, and Am Bm (m, moderately resistant) gyrases are given in Table 5 . The activities of A' Br and Ar Bs gyrases indicated that they were highly resistaht to ciprofloxacin and sparfloxacin (>800 jig/ml, respectively). The ID50s of ciprofloxacin and sparfloxacin against As Bs, As Bi, and As Br gyrases ranged from 15 to 26 ,ug/ml. The activities of Am Bm and Am B5 gyrases indicated that they Were moderately resistant to ciprofloxacin and sparfloxacin.
Accumulation of sparfloxacin and ciprofloxacin. The accumulation of sparfloxacin and ciprofloxacin by S. aureus FDA 209-P, mutant 19, and 6171 is given in Fig. 3 . In S. aureus 19 and 6171 are in progress (16) .
